Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

17.04 -1.15 (-6.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals Plc ADR

< Previous 1 2 3 4 5 Next >
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Analyst Ratings for Centessa Pharmaceuticals
  Within the last quarter, Centessa Pharmaceuticals (NASDAQ:CNTA) has observed the following analyst ratings: 
Via Benzinga
CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a... 
Via Benzinga
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Shareholder Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 08/23/2022 -- Centessa Pharmaceuticals plc is under investigation concerning possible securities laws violations in connection with certain financial statements. 
Via SBWire
Centessa Culls Early-Stage Asset For Inherited Disorder
Via Benzinga
BMO Capital Sees Almost 300% Upside On Centessa Stock
Via Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know
  Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Centessa Pharmaceuticals plc Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – CNTA
From The Rosen Law Firm, P.A.
Via Business Wire
Goldman Sachs Maintains Neutral Rating for Centessa Pharmaceuticals: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of Centessa Pharmaceuticals (NASDAQ:CNTA) and lower its price target from $5.00 to $4.00. Shares of Centessa Pharmaceuticals are trading down... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Centessa Pharmaceuticals: Q2 Earnings Insights
  Centessa Pharmaceuticals (NASDAQ:CNTA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers 
Via Benzinga
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
53 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.